KVUE Stock Recent News

Kenvue Inc. (NYSE:KVUE ) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ET Company Participants Jim Giannakouros - Interim Head, Investor Relations Thibaut Mongon - Chief Executive Officer Paul Ruh - Chief Financial Officer Conference Call Participants Anna Lizzul - BofA Securities, Inc. Steve Powers - Deutsche Bank Securities, Inc. Andrea Teixeira - JPMorgan Securities LLC Nik Modi - RBC Capital Markets LLC Filippo Falorni - Citigroup Global Markets, Inc. Susan Anderson - Canaccord Genuity Jeremy Fialko - HSBC Peter Grom - UBS Operator Hello and welcome to the Kenvue Second Quarter 2024 Earnings Conference Call. All lines have been placed on mute to prevent any background noise.

Kenvue (KVUE) shares surged in intraday trading Tuesday after the company affirmed its full-year guidance that topped analysts' expectations.

Among the key stocks in focus in today's session is Kenvue (NYSE: KVUE ). The company, which was spun off from parent Johnson & Johnson (NYSE: JNJ ) almost exactly one year ago, is seeing strong traction in the market today.

Shares of the Band-Aid parent are on track for their largest daily percent increase on record.

Although the revenue and EPS for Kenvue (KVUE) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Kenvue (KVUE) came out with quarterly earnings of $0.32 per share, beating the Zacks Consensus Estimate of $0.28 per share. This compares to earnings of $0.32 per share a year ago.

Shares in Kenvue Inc (NYSE:KVUE) were up 9% in pre-market trading after the company exceeded Wall Street's expectations for second-quarter profit and revenue. The consumer health company, spun off from Johnson & Johnson (NYSE:JNJ) last year, reported strong sales in its essential health products unit, which includes Tylenol, Listerine, and Neutrogena.

Shares of Kenvue Inc. KVUE, -3.35% jumped 3.4% in premarket trading Tuesday, after the parent of consumer health brands including Band-Aid, Tylenol and Listerine reported second-quarter earnings that beat expectations, boosted by productivity gains and higher pricing. Net income fell to $58 million, or 3 cents a share, from $430 million, or 23 cents a share, in the year-ago period.

Kenvue beat Wall Street estimates for second-quarter profit and revenue on Tuesday, helped primarily by better-than-expected sales in its essential health products unit that sells brands including Band-Aid, Listerine and Carefree.

SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) (“Kenvue”), today announced financial results for the fiscal second quarter ended June 30, 2024.